A world-class team of scientists and drug developers

Our experienced and proven team combines experts in drug and medical countermeasure development and regulatory strategy with world-leading scientists in the chemistry and biochemistry of heavy metals and radioisotopes, making us uniquely positioned to successfully deliver our first and class-leading drug candidate to the market.

Team

Avatar

Julian Rees, PhD

CEO & Co-Founder

Avatar

Rebecca Abergel, PhD

CSO & Co-Founder

Avatar

Hannah Weber, MBA, MPH

Vice President, Strategy & Business Development & Co-Founder

Avatar

Jody Khouri, PMP, CA-AM

Vice President, Program, Portfolio, & Alliance Management

Avatar

Michelle Rose, PhD

Head of Regulatory

Avatar

Mark Sorenson, PhD

Head of CMC Development

Avatar

Sulin Shah, JD

General Counsel

Avatar

Laura Vega, PMP, EVP

Director, FP&A / Program Contract Financial Management

Avatar

Josh Godshaw

Associate Director, Quantitative Science

Avatar

T.J. Yokley, PhD

Scientist, Discovery Research

Avatar

Ariana Robertson

Project Coordinator

Avatar

Daniel Mulugeta

Senior Research Associate

Avatar

Madison Pearson

Research Associate

Avatar

Dmitry Zamoryakhin, MD, MBA

Clinical Development Consultant

Avatar

JP Clement, MD

Pharmacovigilance Consultant

Avatar

Jennifer True

Pharmacovigilance Operations Consultant

Advisors

Frequently Asked Questions


  1. Are any of your drugs FDA-approved?
    No, our drug products have not been approved by the FDA, and any conclusions regarding safety or efficacy for any use or indication are based solely on preclinical studies in animal models. The FDA has granted an Investigational New Drug application for our lead drug candidate HOPO-101 and a Phase 1 clinical trial is ongoing. Full Disclaimer

  2. Can you answer questions or provide medical advice about metal toxicity or chelation treatments?
    No, we cannot provide any medical advice. Questions about exposure to or toxicity from heavy metals, courses of treatment, recommended chelators, symptoms related to heavy metal contamination, or any other heath-related topics should be directed to your physician.

  3. What can I do to stay informed about your progress?
    Keep an eye on our website, or join our mailing list.

  4. When will you be starting clinical trials?
    The Phase 1 clinical trail evaluating safety and pharmacology of HOPO 14-1 has launched, and is being conducted by SRI International. More information is can be found at https://clinicaltrials.gov/ct2/show/NCT05628961

  5. Can I sign up to participate in a clinical trial?
    We are not currently enrolling participants in any clinical trials. When we have funding and approval to begin enrolling clinical trials, we will make announcements on our website and via our mailing list - please consider signing up if you would like to be notified.

  6. I still have questions - who can I contact for more information?
    Our contact information is here. We regret that due to a large volume of inquiries, it may take us some time to reply depending on the nature of your message. We need to reiterate that our products are not available for sale or distribution at this time.